I agree Dave. ICON has labs all over the world. AMBS does not have the capability to reach ex-US, but ICON does. ICON just might pay AMBS for rights to ex-US markets for Lympro in clinical trials. Just a guess. That makes the most sense to me at this point but could be a myriad of things.